Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $359.46 million
P/E Ratio 55.56
Dividend Yield 0.00%
Shares Outstanding 726.18 million
Earnings per share -0.563
Dividend per share 0.12
Year To Date Return -46.41%
Earnings Yield 1.80%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Healius Ltd (ASX: HLS)
    Latest News

    Scientist taking down notes from a tablet, with two other scientists working in the background.
    Healthcare Shares

    Healius vs Australian Clinical Labs: Which ASX pathology share wins?

    Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

    Read more »

    Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices.
    Broker Notes

    6 ASX shares upgraded by experts amid a weak market 

    Brokers have increased their ratings on Capricorn Metals, REA Group, and others this week. 

    Read more »

    Broker written in white with a man drawing a yellow underline.
    Broker Notes

    Buy, hold, sell: Netwealth, Tabcorp, Healius shares

    Let's check out some new ratings on ASX shares today.

    Read more »

    Woman and man at work looking at data on a tablet at work.
    Broker Notes

    Buy, hold, sell: Judo Capital, Healius, BHP shares

    Morgans has issued new notes on several stocks including BHP, which hit a new record today.

    Read more »

    Five healthcare workers standing together and smiling.
    ASX Share Market News

    ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

    Healthcare outperformed while the ASX 200 weakened as earnings season continued last week.

    Read more »

    Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
    Earnings Results

    Healius posts FY26 revenue growth, narrows underlying loss

    Its underlying loss narrowed, but its reported loss after tax widened to $415.6 million.

    Read more »

    Worried man watching his smartphone.
    ASX Share Market News

    These are the 10 most shorted ASX shares

    Short sellers have their eyes on these shares.

    Read more »

    Devastated man with his head on his office desk with paperwork and a laptop.
    ASX Share Market News

    Which are the 10 most shorted ASX shares?

    Short sellers have their eyes on these shares.

    Read more »

    Buy and sell written on silver cubes on a stock market chart.
    Broker Notes

    Buy, hold, sell: Southern Cross Gold, Healius, Centuria Office REIT shares

    Experts reveal their ratings and 12-month targets on this gold explorer, healthcare provider, and ASX REIT.

    Read more »

    A male party goer sits wearing a party hat and with a party blower in his mouth amid a bunch of balloons with a sad, serious look on his face as though the party is over or a celebration has fallen flat.
    Broker Notes

    5 ASX shares downgraded by brokers this week

    Brokers reduced their ratings on CSL, Graincorp, and other stocks this week.

    Read more »

    A group of three young men sit on a sofa in a home environment with a bowl of popcorn and beer bottles in front of them cheering on one of their teams on a phone.
    Broker Notes

    Buy, hold, sell: Aristocrat, Breville, and Healius shares

    Let's see what Morgans is saying about these shares this week.

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Healthcare Shares

    Why is this ASX 300 share crashing over 20% today?

    It is a very red day for this healthcare stock. What's happening? Let's find out.

    Read more »

    Frequently Asked Questions

    Yes, Healius has historically paid two fully franked shareholder dividends a year.

    Healius has generally paid its shareholder dividends in March/April and September/October.

    Healius Ltd listed on the ASX on 3 July 1998.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    09 May 2025 $0.4130 100.00% Special Cash 23 May 2025
    07 Sep 2022 $0.0600 100.00% Final 21 Sep 2022
    24 Mar 2022 $0.1000 100.00% Interim 05 Apr 2022
    13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
    25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
    26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
    29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
    15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019

    HLS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Healius Ltd

    Healius Ltd (ASX: HLS) operates a network of pathology laboratories and collection centres across Australia.

    The company is Australia's second-largest pathology provider, with around 2,000 collection sites and close to 100 pathology laboratories operating under a portfolio of brand names, including Laverty Pathology, Dorevitch Pathology, QML Pathology, and Western Diagnostic Pathology.

    Following the May 2025 sale of its Lumus Imaging business, Healius now focuses on pathology and its bioanalytical laboratory services business, Agilex Biolabs.

    HLS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 Oct 2026 $0.49 $0.00 0.00% 3,729,256 $0.48 $0.50 $0.47
    28 Oct 2026 $0.49 $0.03 6.59% 2,581,816 $0.45 $0.49 $0.45
    27 Oct 2026 $0.46 $0.02 4.55% 1,405,985 $0.44 $0.46 $0.44
    26 Oct 2026 $0.44 $0.01 2.30% 5,361,335 $0.44 $0.45 $0.41
    23 Oct 2026 $0.44 $0.02 4.82% 4,066,471 $0.41 $0.45 $0.41
    22 Oct 2026 $0.42 $0.02 5.13% 2,944,131 $0.39 $0.42 $0.39
    21 Oct 2026 $0.39 $0.00 0.00% 1,347,356 $0.39 $0.41 $0.39
    20 Oct 2026 $0.39 $0.01 2.63% 438,080 $0.39 $0.39 $0.38
    19 Oct 2026 $0.38 $0.01 2.67% 2,754,702 $0.37 $0.40 $0.37
    16 Oct 2026 $0.38 $0.01 2.70% 1,571,054 $0.37 $0.39 $0.37
    15 Oct 2026 $0.37 $-0.01 -2.63% 2,953,906 $0.38 $0.38 $0.37
    14 Oct 2026 $0.38 $-0.01 -2.60% 4,833,748 $0.38 $0.39 $0.37
    13 Oct 2026 $0.39 $-0.01 -2.56% 10,787,465 $0.39 $0.39 $0.37
    12 Oct 2026 $0.39 $0.00 0.00% 2,479,968 $0.40 $0.40 $0.38
    09 Oct 2026 $0.39 $-0.01 -2.50% 799,109 $0.40 $0.40 $0.39
    08 Oct 2026 $0.40 $-0.01 -2.44% 1,227,178 $0.41 $0.41 $0.40
    07 Oct 2026 $0.41 $0.00 0.00% 2,719,041 $0.41 $0.41 $0.40
    06 Oct 2026 $0.41 $0.00 0.00% 4,501,124 $0.40 $0.43 $0.40
    05 Oct 2026 $0.41 $0.01 2.53% 1,346,073 $0.40 $0.42 $0.40
    02 Oct 2026 $0.40 $-0.02 -4.76% 3,334,024 $0.43 $0.43 $0.40
    01 Oct 2026 $0.42 $-0.01 -2.33% 6,096,510 $0.43 $0.44 $0.42
    30 Sep 2026 $0.43 $0.02 4.82% 4,731,644 $0.42 $0.44 $0.41

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    27 Oct 2026 Paul Anderson Issued 117,433 $45,000
    Issue of securities. VWAP
    26 Oct 2026 Christopher Hall Buy 35,000 $15,204
    On-market trade.
    23 Oct 2026 Paul Anderson Issued 4,469,109 $1,944,062
    Director remuneration. 4,469,109 Performance Rights
    23 Oct 2026 Paul Anderson Buy 232,941 $102,959
    On-market trade.
    27 Aug 2026 Sally Evans Transfer 67,782 $29,485
    As advised by the company. as per announcement 27/08/2026
    27 Aug 2026 Sally Evans Transfer 67,782 $29,485
    As advised by the company. as per announcement 27/08/2026
    27 Aug 2026 Katherine (Kathy) Ostin Exercise 22,977 $9,994
    Conversion of securities.
    27 Aug 2026 Katherine (Kathy) Ostin Buy 22,977 $9,994
    Conversion of securities.
    18 Aug 2026 Paul Anderson Expiry 305,462 $135,930
    As advised by the company. rights lapsed
    29 Jun 2026 Paul Anderson Expiry 75,887 $29,595
    As advised by the company. 305,462 rights, rights Lapsed
    23 Apr 2026 Katherine (Kathy) Ostin Exercise 22,978 $12,408
    Conversion of securities. 22977 Share Rights
    23 Apr 2026 Katherine (Kathy) Ostin Issued 22,978 $12,408
    Conversion of securities.
    12 Mar 2026 Katherine (Kathy) Ostin Buy 8,547 $4,999
    On-market trade.
    12 Mar 2026 Steven Rubic Buy 130,000 $77,350
    On-market trade. Average price
    09 Mar 2026 Katherine (Kathy) Ostin Buy 16,264 $9,999
    On-market trade. Average price
    04 Mar 2026 Katherine (Kathy) Ostin Buy 23,079 $14,999
    On-market trade. Average price per share
    18 Nov 2025 Paul Anderson Buy 54,431 $47,899
    On-market trade.
    10 Nov 2025 Katherine (Kathy) Ostin Issued 45,955 $39,999
    Director remuneration. VWAP, 45,955 Share Rights
    31 Oct 2025 Paul Anderson Buy 57,471 $50,976
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Christopher John Hall Non-Executive Director Sep 2025
    Mr Hall brings to the Board experience across asset management, superannuation and, recently, biotechnology. His career has included roles as Chair, Non Executive Director and Chief Investment Officer, along with senior executive positions in Australia and Hong Kong. Chris current roles include Chair of BiomeBank, Non Executive Director, Investment Committee Chair and Audit Committee Member of AMP Super, Non Executive Director and Chair of the Audit & Risk Committee of Funds SA, Investment Committee Chair of Perks Private Wealth, Member of the Advisory Board to the Long Term Value Fund at Tanarra Capital, and a Member of the Merlon Capital Partners Advisory Board.
    Mr Paul Anderson Chief Executive OfficerManaging Director Mar 2024
    Mr Anderson earlier held the position of Group Chief Financial Officer. Paul is a business leader with a background in industries facing disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & New Zealand. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
    Professor Bruce Gregory Robinson AC Non-Executive Director Feb 2026
    Prof Robinson has 25 years experience as a leader in healthcare. Professor Robinson currently serves on the boards of a number of listed healthcare entities. Professor Robinson former roles include Chair of the Australian Government taskforce of expert clinicians charged with reviewing the Medicare Benefits Schedule, the Medical Benefits Schedule Review Taskforce, and chair of Australias peak advisory and funding body for medical research, the National Health and Medical Research Council. He is a former Dean of the University of Sydney Medical School, the former head of the Cancer Genetics Unit at the Kolling Institute, Royal North Shore Hospital, and the former Head, Division of Medicine, Royal North Shore Hospital.
    Ms Kathryn (Kate) Mary McKenzie Non-Executive ChairmanNon-Executive Director Feb 2021
    Ms McKenzie is a Chief Executive Officer and Non-Executive Director. Kates executive career included over 30 years experience in the telecommunication and government sectors in Australia, New Zealand and Hong Kong. Kate held several senior roles at Telstra from 2004 to 2016 the last of which was as Chief Operating Officer and 7 years in senior roles in the NSW Government including as Director General of the NSW Department of Industrial Relations. Kate also served 3 years as Chief Executive Officer of Chorus, New Zealand provider of telecommunications infrastructure before commencing her Non-Executive Director career in 2019. She is a member of both the Risk Management Committee and the People, Governance Committee.
    Ms Sally Evans Non-Executive Director Aug 2018
    Ms Evans has over 30 years experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the Asia Pacific region. Sally is a Non Executive Director of Allianz Australia Life Holdings Ltd and related entities, and a number of Opal Healthcare entities. She is Chair of the People, Governance Committee and a member of the Risk Management Committee.
    Ms Katherine (Kathy) Ostin Non-Executive Director Dec 2024
    Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia and the UK. She is a member of the People, Governance Committee.
    Mr Charlie Taylor Non-Executive Director Mar 2023
    Mr Taylor has over 30 years experience in international advisory, having retired, in 2020, as a Senior Partner at McKinsey & Company. He has advised many of Australias private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. He is a Senior Advisor at GNG Partners and recently retired as Chair of the NSW Innovation and Productivity Council. He is a member of the People, Governance Committee.
    Mr Steven Rubic Non-Executive Director Dec 2025
    Mr Rubic has over 30 years of executive leadership in healthcare including leading national areas of operations. He has held CEO positions at St Vincent and Mater Health Sydney, I MED Radiology Network and Healthscope. Steven is also a Non Executive Director. He is currently a Non Executive Director of the Mater Hospitals Group and CHL aged care business and the Deputy Chair of private equity owned InvoCare.He is a chair of the Risk management committee.
    Ms Gillian Maria Nairn Company Secretary Sep 2026
    -
    Hon Andrew Peter Thomson Company Secretary Oct 2025
    -
    Ms Kylie Brown Company Secretary May 2025
    -
    Gillian Maria Nairn Company Secretary
    -
    Kylie Brown Company Secretary
    -
    Andrew Peter Thomson Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 235,407,337 32.42%
    HSBC Custody Nominees (Australia) Limited 169,613,798 23.36%
    J P Morgan Nominees Australia Pty Limited 86,408,332 11.90%
    BNP Paribas Noms Pty Ltd 16,634,580 2.29%
    HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> 11,649,845 1.60%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 8,997,573 1.24%
    First Samuel Ltd A/CN 086243567 <ANF ITS MDA Clients A/C> 7,403,579 1.02%
    Sandhurst Trustees Ltd <Wentworth Williamson A/C> 4,514,449 0.62%
    Indian Pacific Investments Pty Ltd 3,986,780 0.55%
    LSND Pty Ltd <LSND A/C> 2,876,345 0.40%
    Rinrim Pty Ltd 2,497,161 0.34%
    HSBC Custody Nominees (Australia) Limited A/C 2 2,301,158 0.32%
    Mast Financial Pty Ltd <A To Z Investment A/C> 2,250,000 0.31%
    Kenyon St Medical Centre Pty Ltd 2,000,000 0.28%
    Kinkora Park Pty Ltd <Hawthorn Super Fund A/C> 2,000,000 0.28%
    Mr Kim Bee Tan & Mrs Verna Suat Wah Tan <Perfect Pair Super Fund A/C> 1,800,000 0.25%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 1,703,284 0.23%
    Mr Prajwal Subedi 1,689,000 0.23%
    BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> 1,645,875 0.23%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 1,501,920 0.21%

    Profile

    since

    Note